ED-71 clinical Study Using Alfacalcidol as the Comparator on Bone Mineral Density in Patients With Primary Osteoporosis

Trial Profile

ED-71 clinical Study Using Alfacalcidol as the Comparator on Bone Mineral Density in Patients With Primary Osteoporosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Eldecalcitol (Primary) ; Alfacalcidol
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 06 Nov 2017 According to a Chugai Pharmaceutical media release, regulatory filing for eldecalcitol is planned for 2018 after the results of this trial have been collated in China.
    • 06 Nov 2017 Primary endpoint (Rate of change of bone density of lumbar spine(L1-4 BMD) from baseline values 12 months later) has been met, according to a Chugai Pharmaceutical media release.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top